Ignite Creation Date:
2024-05-05 @ 10:32 PM
Last Modification Date:
2024-10-26 @ 10:20 AM
Study NCT ID:
NCT01124318
Status:
COMPLETED
Last Update Posted:
2010-09-14
First Post:
2010-04-28
Brief Title:
A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults
Sponsor:
Avva Rus JSC
Organization:
Avva Rus JSC
Study Overview
Official Title:
Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Lactofiltrum Orally Administered Tablets Produced by AVVA RUS JSC to Treat Atopic Dermatitis in Adults
Status:
COMPLETED
Status Verified Date:
2010-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LF-AD-09
Brief Summary:
The purpose is to study efficacy of Lactofiltrum in adult patients with atopic dermatitis Lactofiltrum consists of 85 of hidrolytic lignin and 15 of lactulose and acts as an enterosorbent which enables to enhance metabolism and elimination of endotoxins and to normalize metabolic and immune processes Additionally lactulose stimulates Bifidobacterium flora and in aggregate it could improve skin condition afflicted by atopic dermatitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None